TCRX Insider Trading (TScan Therapeutics)

Insider Ownership Percentage: 5.30%
Insider Buying (Last 12 Months): $238,371.14
Insider Selling (Last 12 Months): $0.00

TScan Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at TScan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TScan Therapeutics Share Price & Price History

Current Price: $3.15
Price Change: Price Decrease of -0.22 (-6.53%)
As of 08/16/2022 01:00 AM ET

This chart shows the closing price history over time for TCRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

TScan Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2022David P SouthwellCEOBuy25,000$3.59$89,750.00171,569View SEC Filing Icon  
3/24/2022Brian M. SilverCFOBuy15,000$3.40$51,000.00View SEC Filing Icon  
9/23/2021Zoran ZdraveskiInsiderBuy4,716$7.48$35,275.68View SEC Filing Icon  
9/21/2021Brian M. SilverCFOBuy5,000$6.32$31,600.00View SEC Filing Icon  
9/20/2021Gavin MacBeathInsiderBuy4,943$6.22$30,745.46View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for TScan Therapeutics (NASDAQ:TCRX)

36.97% of TScan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TCRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

TScan Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/16/2022Jane Street Group LLC10,176$32K0.0%N/A0.042%Search for SEC Filing on Google Icon
8/16/2022Woodline Partners LP132,317$0.42M0.0%-3.4%0.551%Search for SEC Filing on Google Icon
8/12/2022LPL Financial LLC16,000$50K0.0%N/A0.067%Search for SEC Filing on Google Icon
5/17/2022RA Capital Management L.P.1,021,764$2.86M0.1%-18.6%4.299%Search for SEC Filing on Google Icon
5/17/2022Hhlr Advisors LTD.669,513$1.88M0.0%-47.8%2.817%Search for SEC Filing on Google Icon
5/16/2022Woodline Partners LP136,930$0.38M0.0%+37.1%0.576%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC13,300$37K0.0%N/A0.056%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.226,929$0.64M0.0%-4.7%0.955%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.1,519,188$4.25M0.0%+1.4%6.392%Search for SEC Filing on Google Icon
4/26/2022Marquette Asset Management LLC28,895$81K0.0%+33.7%0.122%Search for SEC Filing on Google Icon
2/15/2022Deer Management Co. LLC1,245,505$5.61M0.1%N/A5.240%Search for SEC Filing on Google Icon
2/15/2022Adage Capital Partners GP L.L.C.550,000$2.48M0.0%+10.8%2.314%Search for SEC Filing on Google Icon
1/19/2022Marquette Asset Management LLC21,618$97K0.0%N/A0.091%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC22,200$0.19M0.0%N/A0.093%Search for SEC Filing on Google Icon
11/16/2021Wellington Management Group LLP139,566$1.16M0.0%N/A0.582%Search for SEC Filing on Google Icon
11/15/2021RA Capital Management L.P.1,255,317$10.47M0.1%N/A5.238%Search for SEC Filing on Google Icon
11/15/2021Caas Capital Management LP75,000$0.63M0.0%N/A0.313%Search for SEC Filing on Google Icon
11/12/2021DC Investments Management LLC35,563$0.30M0.6%N/A0.148%Search for SEC Filing on Google Icon
11/12/2021DC Funds LP630,000$5.25M20.6%N/A2.629%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.1,500,577$12.52M0.0%N/A6.261%Search for SEC Filing on Google Icon
11/9/2021Monashee Investment Management LLC100,000$0.83M0.2%N/A0.417%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
TScan Therapeutics logo
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More on TScan Therapeutics

Today's Range

Now: $3.15
Low: $3.11
High: $3.51

50 Day Range

MA: $3.36
Low: $2.84
High: $4.39

52 Week Range

Now: $3.15
Low: $1.60
High: $14.71

Volume

25,246 shs

Average Volume

62,800 shs

Market Capitalization

$75.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of TScan Therapeutics?

TScan Therapeutics' top insider shareholders include:
  1. David P Southwell (CEO)
  2. Brian M Silver (CFO)
  3. Gavin Macbeath (Insider)
  4. Zoran Zdraveski (Insider)
Learn More about top insider investors at TScan Therapeutics.

Who are the major institutional investors of TScan Therapeutics?

TScan Therapeutics' top institutional investors include:
  1. Woodline Partners LP — 0.55%
  2. LPL Financial LLC — 0.07%
  3. Jane Street Group LLC — 0.04%
Learn More about top institutional investors of TScan Therapeutics stock.

Which major investors are selling TScan Therapeutics stock?

In the previous quarter, TCRX stock was sold by these institutional investors:
  1. Woodline Partners LP

Which major investors are buying TScan Therapeutics stock?

In the last quarter, TCRX stock was acquired by institutional investors including:
  1. LPL Financial LLC
  2. Jane Street Group LLC
Within the previous year, these company insiders have bought TScan Therapeutics stock:
  1. David P Southwell (CEO)
  2. Brian M Silver (CFO)
  3. Gavin Macbeath (Insider)
  4. Zoran Zdraveski (Insider)
Learn More investors buying TScan Therapeutics stock.